Mantle Cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mantle Cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-12-02FDA Approved: RITUXAN — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for Rituxan (rituximab) filed by Genentech, Inc., resulting in updated labeling for the product.
-
CLINICAL_TRIALS trial_result · 2021-11-19Clinical Trial Update: Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma [Phase 3]
Phase 3 trial update evaluating orelabrutinib with rituximab and combination chemotherapy for newly diagnosed aggressive B-cell non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2021-11-11Clinical Trial Update: A Study of OLR in First-line Treatment of Mantle Cell Lymphoma [Phase 2]
Phase 2 clinical trial update for OLR as first-line treatment in mantle cell lymphoma.
-
FDA approval · 2021-11-04FDA Approved: VELCADE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Velcade (bortezomib) submitted by Takeda Pharmaceuticals America, Inc. This approval covers …
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma [Phase 1]
Phase 1 trial evaluating loncastuximab tesirine with durvalumab in various B-cell lymphomas was terminated; results posted in 2021.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-10-14FDA Approved: LENALIDOMIDE — Original Application (Dr. Reddy's Laboratories Inc.)
The FDA approved Dr. Reddy's Laboratories' original application for lenalidomide (generic), authorizing a generic version of the cancer drug…
-
CLINICAL_TRIALS trial_result · 2021-10-13Clinical Trial Update: Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating venetoclax, lenalidomide, and rituximab in relapsed/refractory mantle cell lymphoma (a relapsed non-Hodgkin lymph…
-
FDA approval · 2021-08-31FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation. The action expands or updates the …
-
CLINICAL_TRIALS trial_result · 2021-08-26Clinical Trial Update: Zanubrutinib-based Induction and Maintenance Therapy in Young and Fit Patients With Untreated Mantle Cell Lymphoma [Phase 2]
A phase 2 clinical trial investigating zanubrutinib-based induction and maintenance therapy in young, fit patients with untreated mantle cel…
-
CLINICAL_TRIALS trial_result · 2021-08-10Clinical Trial Update: Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 2]
Phase 2 trial of enzalutamide for relapsed or refractory mantle cell lymphoma was terminated; results posted in 2021.
-
FDA approval · 2021-08-05FDA Approved: LENALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for lenalidomide by Teva Pharmaceuticals, approving changes related to the drug's use.
-
CLINICAL_TRIALS trial_result · 2021-08-02Clinical Trial Update: A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies [Phase 1, Phase 2]
Phase 1/2 clinical trial of ABT-263 in relapsed or refractory lymphoid malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2021-05-25Clinical Trial Update: Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy [Phase 2]
Phase 2 trial assessing safety and efficacy of RAD001 in mantle cell lymphoma patients refractory or intolerant to Velcade therapy has compl…
-
CLINICAL_TRIALS trial_result · 2021-05-07Clinical Trial Update: Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 trial evaluating lenalidomide with low-dose dexamethasone and rituximab in rituximab-resistant, non-aggressive B-cell lymphomas; com…
-
CLINICAL_TRIALS trial_result · 2021-05-05Clinical Trial Update: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating bortezomib, rituximab, dexamethasone with or without temsirolimus in untreated or relapsed Waldenström macroglobu…
-
CLINICAL_TRIALS trial_result · 2021-04-19Clinical Trial Update: Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients [Phase 1]
Phase 1/open-label pharmacokinetic study assessing interactions between tazemetostat and CYP enzymes and gastric pH in patients with B-cell …
-
CLINICAL_TRIALS trial_result · 2021-03-18Clinical Trial Update: Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
Phase 1 study evaluating idelalisib in combination with various chemotherapeutic, immunomodulatory agents, and anti-CD20 antibody in relapse…
-
CLINICAL_TRIALS trial_result · 2021-02-02Clinical Trial Update: Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma [Phase 2]
Phase 2 trial evaluating acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab in untreated mantle cell lymphoma. The s…
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies [Phase 1]
Phase 1 trial evaluating anti-CD20 radioimmunotherapy before chemotherapy and stem cell transplant in high-risk B-cell malignancies; trial s…
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma [Phase 1]
This Phase I/Ib trial assesses safety and early efficacy signals for nivolumab plus veliparib in patients with advanced solid tumors and agg…
-
CLINICAL_TRIALS trial_result · 2020-10-29Clinical Trial Update: Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) [Phase 2]
Phase 2 study MK-0683-103 evaluated vorinostat in follicular lymphoma, other indolent B-cell non-Hodgkin lymphomas, and mantle cell lymphoma…
-
EMA approval · 2020-10-16First CAR-T cell medicine for mantle cell lymphoma
The EMA announces the first CAR-T cell medicine approved for mantle cell lymphoma, marking a milestone in targeted cellular therapy for this…
-
CLINICAL_TRIALS trial_result · 2020-09-23Clinical Trial Update: Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]
Phase 2 study evaluating entospletinib in adults with relapsed or refractory hematologic malignancies; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2020-09-11Clinical Trial Update: A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL) [Phase 2]
Phase 2 study evaluating TQ-B3525 tablets in relapsed/refractory mantle cell lymphoma (MCL) is in progress, with status currently unknown.
-
CLINICAL_TRIALS trial_result · 2020-09-10Clinical Trial Update: Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2) [Phase 2]
Phase 2 trial update on Tecartus (brexucabtagene autoleucel) for relapsed/refractory mantle cell lymphoma; Cohorts 1 and 2 completed with re…